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Abstract: Recurrent venous thromboembolism (VTE) is associated with increased morbidity 
and mortality. This risk is lowered by anticoagulation, with a large effect in the initial phase 
following the venous thromboembolic event, and with a smaller effect in terms of secondary 
prevention of recurrence when extended anticoagulation is performed. On the other hand, 
extended anticoagulation is associated with an increased risk of major bleeding and thus leads 
to morbidity and mortality. Therefore, it is necessary to assess the risk of recurrence for VTE 
on an individual basis, and a recommendation for secondary prophylaxis should be specifi-
cally based on risk calculation of recurrence of VTE and bleeding. In this review, we provide 
a comprehensive summary of relevant risk factors for recurrent VTE and a practical approach 
for assessing the risk of recurrence in daily practice.
Keywords: thrombosis, hemorrhage, risk assessment
Venous thromboembolism
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and 
pulmonary embolism (PE), is a common disease and presents a major health problem. 
In the general population, the absolute risk of any kind of VTE is 0.1%–0.2% per 
year, and it increases with age. The risk of recurrence after a first episode of VTE is 
5%–7% per year, and it is more than 50 times higher than in patients without previous 
VTE.1 Patients with incident VTE are always at risk for recurrence, regardless of the 
time elapsed since the first event. However, the risk of recurrence does decrease over 
time.2,3 It is important to make a distinction between provoked and unprovoked VTE, 
as the risk of recurrence differs. The adjective “provoked” signifies the occurrence 
of VTE in the presence of an acquired transient risk factor such as recent surgery or 
pregnancy; or a persistent risk factor, such as cancer. When no clinical risk factor can 
be identified, the VTE is called unprovoked or idiopathic.4
Continued anticoagulation after the initial VTE will reduce the risk of recurrence, 
but must be carefully weighed against the risk of treatment, namely anticoagulant-
related bleeding. Thus, it is very important to assess the risk of recurrence in each 
individual patient as to be able to adequately weigh this risk against the risks of long-
term anticoagulation. Estimating the risk of recurrent VTE is complex and requires 
consideration of relevant risk factors for recurrent VTE.
The optimal duration of anticoagulation after VTE has been debated for years. 
Based on a number of studies and meta-analyses, the current American College of 
Chest Physicians (ACCP) Guidelines, published in 2012,5 recommend the following 
(Table 1).
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It is important to make a distinction between acute therapy 
and secondary prophylaxis. In the acute phase, a minimal 
duration of anticoagulation is needed to prevent thrombus 
extension and embolism, and to ensure that the activated 
inflammatory and coagulation processes have returned to 
baseline.6 Beyond this required minimal duration of antico-
agulation, secondary prophylaxis aims to prevent recurrent 
VTE, as even adequate anticoagulation during the acute phase 
cannot lower the risk of recurrence to the same level as in 
patients who have never had a VTE. Thus, anticoagulation 
does not cure VTE.7
The risk of recurrence of VTE after discontinuation of 
anticoagulation is primarily dependent on two factors. First, 
whether the acute VTE was treated effectively, including 
the minimally required duration of anticoagulation. Second, 
the presence of intrinsic risk factors that are known to pro-
mote recurrence, such as thrombophilia or malignancy.
There is a high probability of such intrinsic risk fac-
tors being present in patients with a first time episode of 
unprovoked proximal DVT, and in patients with recurrent 
unprovoked VTE, even if no such risk factor can be estab-
lished at the time. Therefore, long-term anticoagulation is 
recommended in these cases.
But what does “long-term” mean? The ACCP Guidelines5 
suggest continuing anticoagulation until either the risk of 
recurrent VTE no longer clearly outweighs the increased 
risk of bleeding, or until the patient prefers to stop treatment, 
even if the weighing of risks and benefits would support 
continuation. As the risks vary greatly between individual 
patients, there is no universally recommended duration of 
anticoagulation beyond the minimally required one. Thus, 
the decision is left to the treating physician and the patient. 
Therefore, physicians need to have a good estimate of these 
risks in order to correctly weigh the risks and benefits. It 
is important to prevent recurrence of any type of VTE, but 
especially of fatal PE as worst outcome.
Risk of bleeding
Incidence of major bleeding while on anticoagulation varies 
among patient populations and across studies, but is estimated 
at 1%–4% per year with 0.4%–1.5% intracranial bleeding. 
Rates of major bleeding at 14, 90, and 180 days are 0.6%, 
1.0%, and 1.1%, respectively. The 14- and 30-day case fatality 
rates after major bleeding are 8% and 25%.8,9 Increased risk 
of bleeding has been associated with the following factors: 
Age .65 years, previous bleeding, cancer (metastatic or 
not), renal failure, liver failure, thrombocytopenia, previous 
stroke, diabetes, anemia, antiplatelet therapy, poor antico-
agulant control, alcohol abuse, frequent falls, recent surgery, 
comorbidity, and reduced functional capacity.10 There are 
Table 1 Duration of anticoagulation in patients with acute DVT of the leg5
Type of VTE Duration of treatment Recommendation
Provoked isolated distal DVT 3 monthsa Grade 1B
Unprovoked isolated distal DVT 3 months,a then evaluation of risk–benefit ratio  
of extended therapy
Grade 1B
For low or moderate bleeding risk → 3 months Grade 2B
For high bleeding risk → 3 months Grade 1B
Provoked proximal DVT 3 months Grade 1B
Unprovoked proximal DVT At least 3 months, then evaluation of risk–benefit  
ratio of extended therapy
Grade 1B
For low or moderate bleeding risk → extended  
anticoagulant therapyb
Grade 2B
For high bleeding risk → 3 months Grade 1B
Second unprovoked DVT For low bleeding risk → extended anticoagulant  
therapyb
Grade 1B
For moderate bleeding risk → extended  
anticoagulant therapyb
Grade 2B
For high bleeding risk → 3 months Grade 2B
DVT and active cancer For low or moderate bleeding risk → extended  
anticoagulant therapyb
Grade 1B
For high bleeding risk → extended anticoagulant 
therapyb
Grade 2B
Notes: initial and long-term therapy for Pe is the same as for proximal DVT. incidentally found asymptomatic DVT is suggested to be treated with initial and long-term 
anticoagulation as for comparable patients with symptomatic DVT (Grade 2B). aif decision has been made to treat with anticoagulant therapy; bin patients who receive 
extended anticoagulant therapy, the continuing use of treatment should be reassessed at periodic intervals (eg, annually), patient preference considered, and the choice of 
anticoagulant regimen reevaluated.
Abbreviations: DVT, deep vein thrombosis; Pe, pulmonary embolism.
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several scores to assess bleeding risk in patients with atrial 
fibrillation. HAS-BLED is an acronym for hypertension, 
abnormal renal/liver function, stroke, bleeding history or 
predisposition, labile international normalized ratio (INR), 
elderly, drugs/alcohol usage.11 Major bleeding is defined in 
the HAS-BLED study as intracranial, requiring hospitaliza-
tion, decrease in hemoglobin of more than 2 g/L, and/or 
transfusion. Another score, the ATRIA (anticoagulation and 
risk factors in atrial fibrillation) study, used a five-variable 
risk score to predict warfarin-associated hemorrhage in a 
large community-based cohort of patients with atrial fibril-
lation.12 The HEMORR2HAGES-score also predicts bleed-
ing in patients with atrial fibrillation.13 All three of these 
bleeding risk-estimation scores demonstrated only a modest 
performance in predicting clinically relevant bleeding. The 
HAS-BLED performed better than the ATRIA and HEMOR-
R2HAGES scores, as reflected by the receiver operating char-
acteristic (ROC) analysis.14 An additional scoring system, the 
RIETE score, was developed specifically for VTE patients, 
and is similar to the ATRIA score using recent bleeding, crea-
tinine level, anemia, malignancy, symptomatic PE, and age 
as criteria.15 It was developed from a large cohort of patients, 
but has not yet been externally validated. All these scoring 
systems can be helpful to determine whether continuation of 
anticoagulation is in the best interest of VTE patients. The 
RIETE scoring system seems to be particularly useful as it 
is the only scoring system that is derived from a population 
of VTE patients. Its risk score is based on six variables that 
are easily assessed at initial diagnosis, and can identify VTE 
patients at low, intermediate, or high risk for major bleeding 
during the first 3 months of therapy.
Prediction models for  
recurrent VTE
Table 2 summarizes the risk ratio or hazard ratio (HR) of 
recurrent VTE. The Wells score allows probability calcula-
tion based on clinical factors for a first potential VTE event. 
But there are only a few scores for estimating VTE recur-
rence, and they are not as widely used as the Wells score.
One such score is the Vienna prediction model that 
assesses the recurrence in patients with unprovoked VTE.16 
In this model, Eichinger et al16 use sex, location of first 
VTE event, and d-dimer after cessation of anticoagulation 
as predictive variables to estimate cumulative recurrence 
rates of VTE on a nomogram (Table 3). An update of the 
Vienna prediction model has been published, demonstrating 
the usefulness of d-dimer measurements at multiple random 
time points. By integrating these measurements into the 
prediction model, it can now be used at any time from 3 weeks 
to 15 months after discontinuation of anticoagulation.17 
Recently, the Vienna prediction model has been externally 
validated in 904 patients with unprovoked VTE.18 The ability 
of the Vienna prediction model to distinguish risk of VTE 
recurrence in the validation cohort was at least as good as 
in the original cohort, but a c-statistic of 0.63 (vs 0.65 in 
the original derivation cohort) was calculated.18 While the 
validation cohort could confirm the ability of the Vienna 
prediction model to stratify patients according to their risk of 
recurrence, a c-statistic – also known as ROC curve or area 
under curve (AUC) – of 0.63 is rather low and close to 0.5, 
which would mean no power to predict recurrence.
The DASH prediction score uses similar risk factors 
such as elevated d-dimer after anticoagulation (2 points), 
age #50 years (1 point), male sex (1 point), and – in women – 
hormone use at the time of the initial VTE (–2 points) to 
predict VTE recurrence in patients with previous unprovoked 
VTE (Table 3).19 The score was based on a patient-level 
meta-analysis of 1,818 patients with unprovoked VTE. The 
annual recurrence rate associated with DASH scores of –2 
to 4 ranged from 1.8% per year to 19.9% per year. By con-
sidering a low recurrence risk (score below or equal to 1), 
long-term anticoagulation might be avoided in about half the 
patients with unprovoked VTE.19
The “Rodger” or “Men continue and HER DOO2” 
recurrent VTE risk assessment model identified those 
patients at low risk for recurrence who can safely discon-
tinue anticoagulation therapy in a prospective cohort of 
646 patients with unprovoked VTE.20 The overall annual 
risk of recurrence was 9.3% (95% CI [confidence inter-
val], 7.7%–11.3%). The annual risk of recurrent VTE was 
higher among men (13%; 95% CI, 10.8%–17.0%) than 
women (5.5%; 95% CI, 3.7%–7.8%). Men with signs 
Table 2 Risk factors for venous thromboembolism recurrence 
given in relative risk/HR and its 95% Ci
Risk factor Relative risk/hazard 
ratio (95% CI)
Unprovoked proximal DVT21 2.3 (1.8–2.9)
Obesity28 1.6 (1.1–2.4)
Male sex30 2.8 (1.4–5.7)
Positive d-dimer testing33 2.6 (1.9–3.5)
Residual thrombosis36 1.5 (1.1–2.0)
Hereditary thrombophilia37 1.5 (1.1–1.9)
Inflammatory bowel disease40 2.5 (1.4–4.2)
Antiphospholipid antibody41 2.4 (1.3–4.1)
Asian and Pacific Islander ethnicity42 0.7 (0.5–0.9)
Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; HR, hazard 
ratio.
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and symptoms of post-thrombotic syndrome (hyperpig-
mentation, edema, or redness in either leg) had a very 
high annual risk of recurrence (24%). Women with two 
or more risk factors, namely post-thrombotic syndrome, 
d-dimer level of $250 µg/L during anticoagulation, body 
mass index (BMI) of $30 kg/m2, or age of $65 years, are 
at high risk for recurrent VTE and should thus continue 
anticoagulation.20 Women with 0 or 1 of these risk factors 
have a low annual risk of VTE recurrence (1.6%) and can 
thus safely discontinue anticoagulation therapy.20 Unfortu-
nately, in men no subgroup with low risk of VTE recurrence 
could be identified. All these risk prediction models are 
limited by the absence of a large prospective trial identify-
ing the best model for risk stratification.
Proximal and distal DVT and risk  
of recurrence
Patients with an unprovoked VTE have a higher rate of recur-
rence after discontinuation of anticoagulation compared with 
those with a provoked VTE.
In a cohort study of 1,626 patients with provoked or 
unprovoked proximal DVT or PE, Prandoni et al21 could 
demonstrate that after discontinuation of anticoagula-
tion and a median follow-up of 50 months, 22.3% of all 
patients had recurrence. Patients with an unprovoked first 
episode of VTE had the highest risk of recurrence with a 
HR of 2.3 (95% CI, 1.8–2.9) compared with those with a 
provoked one.21 Isolated distal DVT refers to thrombosis 
of the infrapopliteal veins without concomitant thrombosis 
of the more proximal veins or PE. It represents half of all 
cases of lower limb DVT. In the prospective, observational, 
multicenter OPTIMEV study, the annual incidence of 
overall VTE recurrence was 2.7% (95% CI, 1.9%–3.8%). 
VTE events recurred more often in isolated proximal DVT 
than distal DVT with a HR of 1.8 (95% CI, 1.1–3.0).22. In a 
multivariate Cox proportional HR model, the authors found 
several predictive factors for recurrence after stopping 
anticoagulation in patients with isolated distal DVT. These 
factors were age over 50 years (HR, 3.7; 95% CI, 1.0–10.6), 
unprovoked DVT (HR, 3.1; 95% CI, 1.4–6.9), and multiple 
unilateral or bilateral DVT (HR, 2.9; 95% CI, 1.4–6.1 and 
HR, 4.0; 95% CI, 1.4–11.1, respectively). The annual risk 
of VTE recurrence was 3.8% (95% CI, 0.3%–2.3%) for 
age over 50 years, 3.8% (95% CI, 2.6%–5.6%) for unpro-
voked distal DVT, 4.9% (95% CI, 3.1%–7.8%) for multiple 
unilateral thrombosis, and 8.9% (95% CI, 3.7%–21.4%) 
for bilateral DVT.22 Thus, whether distal DVT should be 
treated with anticoagulants at all is still a matter of debate. 
However, patients over the age of 50 with distal DVT that 
was unprovoked or involved several veins in one or both 
legs were found to be at significant risk for VTE recurrence. 
Thus, the threshold to treat these patients with anticoagula-
tion therapy should be low.
DVT and PE are regarded as manifestations of the same 
disease, namely, VTE. It is unknown why some patients 
present with PE and others with symptomatic DVT alone. 
However, the initial presentation has an impact on the mode 
of VTE recurrence. Baglin et al23 showed in a patient-level 
meta-analysis that the 5-year rate of any VTE recurrence was 
22% in patients initially presenting with PE, and 26.4% in 
patients initially presenting with DVT. The risk of recurrence 
as PE was 3.1-fold greater in patients initially presenting with 
symptomatic PE than in patients with proximal DVT (HR, 3.1; 
95% CI, 1.9–5.1).23 Patients with proximal DVT had a 4.8-fold 
higher cumulative recurrence rate than those with distal DVT 
(HR, 4.8; 95% CI, 2.1–11.0), as also seen in the prospective 
Table 3 Prediction models for recurrent venous thromboembolism
Model name Vienna prediction model16 DASH score19 Rodger or men continue and 
HER DOO2 score20
Number of patients 929 1,818 646
Design Prospective cohort study Patient-level meta-analysis Prospective cohort study
Predictive variables Male . female. Pe . proximal DVT .  
distal DVT. elevated d-dimer after AC
d-dimer abnormal after cessation of AC 
(2 points). Age #50 years (1 point).  
Sex – male (1 point). Hormonal use at  
VTe onset (–2 points)
Men continue. Hyperpigmentation 
(1 point). edema (1 point). Redness 
(1 point). d-dimer $250 µg/L 
during AC (1 point). Obesity  
(BMi $30 kg/m2) (1 point).  
Old (age $65 years) (1 point)
Total score 0 to 350 –2 to 4 0 to 6
Annual risk of recurrence 2%–15% depending on total score  
(nomogram)
Score of #1: 3.1% women with score of #1: 1.6%
Score of 2: 6.4% women with score of $2: 14.1%
Score of $3: 12.3% Men: 13.7%
Abbreviations: DVT, deep vein thrombosis; VTe, venous thromboembolism; AC, anticoagulation; BMi, body mass index; Pe, pulmonary embolism.
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study by Galanaud et al22 and Baglin et al.23 It is important to 
note for clinical care that patients with a first episode of PE 
are at the same risk for VTE recurrence as patients with DVT 
alone. However, PE patients are three times more likely to suf-
fer another PE than a DVT as recurrence. Given the fact that 
the risk of fatal PE is two to four times greater in PE patients, 
the threshold of extending anticoagulation therapy beyond 3 
months should be low in these patients.
Transient risk factors during the first episode of VTE 
such as major surgery, hospitalization for acute medical ill-
ness and trauma or fracture do not appear to raise the risk for 
recurrent VTE.24,25 However, a systematic review of prospec-
tive cohort studies and randomized trials of patients with a 
first episode of symptomatic VTE provoked by a transient 
risk factor and treated for at least 3 months showed – after 
stopping anticoagulation therapy – an annual recurrence 
rate of 3.3% per patient-year for all patients with a transient 
risk factor, 0.7% per patient-year in the subgroup with a 
surgical factor, and 4.2% per patient-year in the subgroup 
with a nonsurgical factor.26 In the same studies, the rate of 
recurrence after unprovoked VTE was 7.4% per patient-year. 
Thus, the presence or absence of a transient risk factor at 
the time of VTE strongly affects the risk of recurrence after 
anticoagulant therapy is stopped. The risk of recurrence is 
low if VTE is provoked by surgery, intermediate if provoked 
by a nonsurgical risk factor, and high if unprovoked. These 
risks should be considered when deciding on extending 
anticoagulation therapy.26
A family history of VTE, meaning at least one first-degree 
family member affected by VTE, does not appear to raise 
the risk of recurrence.27
Obesity and risk of VTE recurrence
Increased BMI at the time of incident VTE seems to predict 
recurrence.2,7 In a large cohort study of 1,107 patients with 
VTE, Eichinger et al28 found that 4 years after discontinuation 
of anticoagulation therapy, the adjusted HR of recurrence 
was 1.3 (95% CI, 0.9–1.9) (P=0.20) among overweight 
patients and 1.6 (95% CI, 1.1–2.4) (P=0.02) among obese 
individuals compared with patients of normal weight. 
These data suggest that obesity is an important risk factor 
for recurrent VTE and should be taken into account when 
assessing the risk and benefit of anticoagulation therapy 
beyond 3 months.
Male sex and risk of VTE recurrence
Several studies have shown that risk of recurrence is higher in 
male patients. A meta-analysis of 15 studies (nine randomized 
controlled trials and six prospective  observational studies) 
enrolling a total of 5,416 patients found a relative risk of 
recurrent VTE of 1.6 (95% CI, 1.2–2) for men compared 
with women.29 In a prospective study of 474 patients with 
a first DVT, provoked or unprovoked, the risk of recurrence 
was 4.1% for men and 1.6% for women per person-year 
during a mean follow-up of 7.3 years (in total 3,477 person-
years).30 Men with an unprovoked first event had a 2.8-fold 
higher risk for recurrence (95% CI, 1.4–5.7) compared with 
women.30 Douketis et al31 found similar results in a more 
recent patient-level meta-analysis of 2,554 patients followed 
for 27 months. Among patients with unprovoked VTE, men 
were twofold more likely than women to suffer recurrent 
VTE (HR, 2.2; 95% CI, 1.7–2.8). In contrast, there was no 
difference in recurrence risk between men and women after a 
first episode of provoked VTE (HR, 1.2; 95% CI, 0.6–2.4).31 
The reason for the increased risk in men remains unknown, 
but it seems clear that men and women do not share the 
same risk of recurrent VTE. Consequently, sex should be 
taken into account for risk stratification and prevention of 
VTE recurrence.
Positive d-dimer testing following 
cessation of anticoagulation
In patients who have elevated d-dimer levels 1 month after 
discontinuation of anticoagulation, the risk of recurrence is 
increased, as several studies have demonstrated. In a ran-
domized controlled trial (PROLONG trial32), patients with 
unprovoked proximal DVT and positive d-dimer testing 
1 month after discontinuation of anticoagulation therapy 
had a benefit if anticoagulation therapy was restarted. Six 
hundred and eight patients had received at least 3 months 
of anticoagulation before therapy was discontinued. After 
1 month, d-dimers were assessed. In 36.8%, testing was 
positive, and these patients were randomized to either restart 
anticoagulation therapy or have no further anticoagulation. 
During follow-up, 6.4% of patients who had had negative 
d-dimer testing developed recurrent VTE. Patients with posi-
tive d-dimer testing without continued anticoagulation had 
recurrence in 15%, while those with positive d-dimer test-
ing with continued anticoagulation had recurrence in 2.9%, 
resulting in a HR of 4.3 (95% CI, 1.2–14.6).32
The results of the PROLONG trial were confirmed in a 
patient-level meta-analysis of seven prospective studies on 
d-dimer testing after cessation of anticoagulation therapy 
with a total of 1,818 patients with first unprovoked VTE.33 
After a mean follow-up of 26.9 months, a multivariate Cox 
regression model, which included patient age, sex, hormone 
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therapy at the time of the index event, BMI, timing of post-
anticoagulation d-dimer testing, and inherited thrombophilia 
as possible confounders, indicated that positive d-dimer test-
ing was associated with a 2.6-fold higher risk of recurrence 
(95% CI, 1.9–3.5).33
In a recent prospective cohort study of 410 adults aged 
75 years or younger with a first unprovoked proximal DVT 
or PE who had completed 3–7 months of anticoagulation 
therapy, serial d-dimer testing was performed and antico-
agulation therapy was not restarted if two d-dimer tests 
were negative.34 Rates of recurrent VTE during an average 
follow-up of 2.2 years were 6.7% (95% CI, 4.8%–9.0%) 
per patient-year overall, 9.7% (95% CI, 6.7%–13.7%) per 
patient-year in men, and 5.4% (95% CI, 2.5%–10.2%) per 
patient-year in women with VTE not associated with estro-
gen therapy.34 Thus, the risk of VTE recurrence in patients 
with an unprovoked proximal VTE who have negative 
d-dimer is not low enough to justify stopping anticoagulation 
therapy in men, but may be low enough to justify stopping 
therapy in women. These results support the fact that male 
sex is an independent risk factor for VTE recurrence, and 
should be strongly considered in balancing risks and benefits 
of extending anticoagulation.
Residual venous thrombosis  
and risk of VTE recurrence
After an acute DVT, recanalization of the thrombosed 
vein takes time. In a study of 258 patients with proximal 
DVT, Siragusa et al35 demonstrated that after 3 months 
of anticoagulation therapy, there was residual thrombo-
sis – defined as thrombosis of more than 40% of the vein 
diameter – in 69.8% of patients. Anticoagulation therapy 
was stopped in patients without residual thrombosis. 
Those patients with residual thrombosis were randomized 
to either stop therapy or continue anticoagulation (INR, 
2.0–3.0) for 9 additional months. After a follow-up period 
of 2 years, patients without residual thrombosis at the 
beginning of the study had VTE recurrence and/or major 
bleeding in only 1.3%, whereas recurrent events occurred 
in 27.2% of those patients with residual thrombosis who 
did not continue anticoagulation. The HR for patients with 
residual thrombosis and discontinued anticoagulation was 
24.9 (95% CI, 3.4–183.6) compared with patients without 
residual thrombosis. It should be noted that the CI was 
very wide as an indication of a certain imprecision of the 
data.35 A  meta-analysis of 14 studies on residual thrombosis 
showed only a slight increase in risk of recurrence (HR, 1.5; 
95% CI, 1.1–2.0).36
Hereditary thrombophilia and risk 
of VTE recurrence
In patients with mild thrombophilia, specifically heterozy-
gous forms of Factor V Leiden and prothrombin mutation, the 
relative risk of recurrent VTE is only slightly elevated at 1.5 
(95% CI, 1.1–1.9) and 1.4 (95% CI, 1.0–1.8), respectively. 
As such, in the absence of other risk factors, an extended 
anticoagulation is not warranted based on mild thrombophilia 
alone.37 A Cochrane analysis, published in 2009, did not 
report any randomized controlled trials on use of thrombo-
philia screening to assess the risk of recurrence.38 An update 
in 2012 still could not find any data from controlled studies 
to support a recommendation on thrombophilia screening 
in this setting.39
Inflammatory bowel disease  
and risk of VTE recurrence
Inflammatory bowel disease (IBD) significantly increases the 
risk of a first VTE and also increases the risk of recurrence. In 
a prospective study of 2,811 patients with IBD compared to 
subjects without IBD it was demonstrated that the probability 
of recurrence 5 years after discontinuation of anticoagulation 
therapy was higher among patients with IBD than in those 
without (33.4%; 95% CI, 21.8%–45.0% vs 21.7%; 95% CI, 
18.8%–24.6%; P=0.01). After adjustment for potential con-
founders, IBD was an independent risk factor for recurrence 
(HR, 2.5; 95% CI, 1.4–4.2; P=0.001).40
Antiphospholipid antibodies  
and risk of VTE recurrence
Presence of antiphospholipid antibodies indicates a clearly 
elevated risk of recurrence of VTE. One hundred and sixty 
patients with antiphospholipid antibody syndrome who had 
previous venous or arterial thromboembolism were evalu-
ated in a retrospective study by Pengo et al.41 The HR for 
recurrence after discontinuation of anticoagulation therapy 
was 2.4 (95% CI, 1.3–4.1) compared with patients in whom 
therapy was continued.41
Ethnicity and risk of VTE recurrence
In a large epidemiologic study from California including more 
than 23,000 patients with provoked or unprovoked DVT, the 
incidence of recurrent VTE was analyzed in various subgroups. 
In patients of Asian or Pacific Islander ethnicity, the risk of 
recurrence was 0.7 times lower than in the Caucasian popu-
lation (95% CI, 0.5–0.9).42 Hispanic and African  American 
ethnicity did not seem to have a higher risk of  recurrent VTE 
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(1.0 [95% CI, 0.8–1.1] and 1.0 [95% CI, 0.9–1.2], respectively) 
compared with the Caucasian population.42
Malignancy and the risk  
of VTE recurrence
The risk of recurrent VTE is increased two- to four-fold in 
patients with active cancer, and 4.2-fold for cancer patients 
undergoing chemotherapy.2,43
In a prospective cohort of 842 VTE patients on anticoagu-
lant therapy with warfarin, including 181 with known cancer 
at inclusion, Prandoni et al43 noted a 12-month cumulative 
incidence of recurrent thromboembolism of 20.7% (95% 
CI, 15.6%–25.8%) among patients with cancer versus 6.8% 
(95% CI, 3.9%–9.7%) in patients without cancer (HR, 3.2; 
95% CI, 1.9–5.4). Major bleeding was also more common 
among cancer patients and occurred in 12.4% (95% CI, 
6.5%–18.2%) versus 4.9% (95% CI, 2.5%–7.4%) in patients 
without cancer (HR, 2.2; 95% CI, 1.2–4.1).43 Both VTE 
recurrence and bleeding were related to the severity of cancer, 
occurred predominantly during the 1st month of anticoagula-
tion, and were not associated with overanticoagulation. Thus, 
extended anticoagulation is recommended in patients with 
active cancer with or without chemotherapy.44–46
However, it seems that not all cancer patients have the 
same risk of VTE recurrence as shown in the Olmsted County 
cohort. Louzada et al47 performed a retrospective study on 
this population to develop a score and found, in a multivariate 
analysis, that female sex (1 point), lung cancer (1 point), and 
a history of previous VTE (1 point) were associated with an 
increased risk of recurrence. Breast cancer (–1 point) and 
localized cancer disease (TNM stage 1) (–2 points) were 
associated with a lower risk. Patients with a score of #0 had 
low risk (#4.5%) of recurrence, and patients with a score 
of $1 had a high risk ($19%) of VTE recurrence. Similar 
results were found by den Exter et al48 who validated the 
Ottawa prediction rule using a separate patient cohort. 
Lacking a prospective trial, the Ottawa prediction rule for 
recurrent VTE in cancer patients could be used to assess the 
risk of recurrence and in counseling patients on extension 
of anticoagulation therapy.
Discussion
Not all patients with VTE have the same risk of recurrence. 
Even patients with cancer seem to differ in their risk of VTE 
recurrence. Each of the individual risk factors described 
above is important to assess the risk of recurrent VTE, but on 
their own, none of them is specific enough to justify a general 
recommendation for the duration of anticoagulant therapy. 
In most cases, a combination of risk factors needs to be 
considered to more accurately predict the recurrence risk, 
rather than one single risk factor.16
As an example, we discuss a male patient aged 59 who 
has received anticoagulation therapy for 3 months after an 
unprovoked proximal DVT. He has no other comorbidities. 
For how long should anticoagulation therapy as secondary 
prophylaxis be continued? The ACCP guidelines do not give 
a specific recommendation, as the decision needs to be based 
on the absolute risk of recurrence in the individual patient, 
and on the risk of bleeding complications. If we conserva-
tively estimate the absolute risk of recurrence to be 2%–4% 
in this example, and assume a 2.8-fold risk because of male 
sex, the risk increases to 6%–11% per year. If any other risk 
factors listed in Table 2 are present, the baseline risk should 
be multiplied by these HR to estimate risk of recurrence 
more precisely. In the example, an estimated recurrence risk 
of 6%–11% per year can be reason to continue anticoagula-
tion, if the risk of major bleeding is low. In general, a risk 
of VTE recurrence of less than 3% can be used to safely 
discontinue anticoagulation therapy. If the decision has been 
made to extend anticoagulation therapy, the risk of VTE 
recurrence decreases over time after the first event, and the 
risk of anticoagulant-related bleeding increases over time. 
Thus, the need for secondary prophylaxis must be regularly 
reassessed, again based on individual risk factors and on the 
resulting estimated risk of recurrent VTE. Secondary pro-
phylaxis should be stopped if the benefit no longer exceeds 
the risk of bleeding.
If it is decided to discontinue anticoagulation after 
3–12 months due to the risk assessment or because of patient 
preference, low-dose acetylsalicylic acid (ASA) can be 
considered for an additional 3 years.49 The ASPIRE49 and 
WARFASA50 trials were able to demonstrate a reduction in 
recurrent VTE of 32% and a reduction of vascular events – 
arterial and venous combined – of 34% without a significant 
increase in major bleedings.49,51
Conclusion
This review provides a comprehensive summary of important 
risk factors for recurrent VTE that need to be considered 
when planning treatment in the individual patient with VTE. 
It is no longer acceptable to simply recommend “life-long” 
or “indefinite” anticoagulation therapy, even in unprovoked 
proximal DVT or cancer, as not all patients have the same risk 
of recurrence. A personalized risk assessment and tailored 
anticoagulation therapy is essential to improve prevention 
of recurrent VTE.
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